Aspire Biopharma Holdings Inc Financials
Aspire Biopharma Holdings Inc (ASBPW) reported $6K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not product revenue, is carrying Aspire Biopharma as development spending outruns both gross profit and liquidity.
Across FY2022-FY2025, even years with reported profit did not become cash-funded operations, because operating cash flow was negative in every valid annual period. In FY2025, a$5.9M financing inflow more than covered the$4.9M operating outflow, showing that outside capital, not customer activity, carried the year.
Commercial activity is still minimal: FY2025 revenue was only
Liquidity is thinner than the cash balance alone suggests: current assets of
Financial Health Signals
Aspire Biopharma Holdings Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Aspire Biopharma Holdings Inc generated $6K in revenue in fiscal year 2025.
Aspire Biopharma Holdings Inc earned -$16.38 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Aspire Biopharma Holdings Inc held $1.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aspire Biopharma Holdings Inc's gross margin was -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Aspire Biopharma Holdings Inc invested $924K in research and development in fiscal year 2025. This represents an increase of 540.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ASBPW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | N/A | $6K | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $6K | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | -$116 | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $924K+540.0% | $144K | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | $1.3M+37.3% | $976K+3732.6% | $25K |
| Interest Expense | N/A | N/A | N/A | $9K | N/A | N/A |
| Income Tax | N/A | N/A | $1K | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | $4.5M+33.6% | $3.3M+13211.8% | -$25K |
| EPS (Diluted) | — | -$16.38 | -$1.90 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Operating Income.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASBPW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $1.3M+786.7% | $148K-99.3% | $20.0M-93.3% | $300.2M+102274.0% | $293K |
| Current Assets | $1.3M+786.7% | $148K+82.2% | $81K-92.6% | $1.1M+274.4% | $293K |
| Cash & Equivalents | $1.0M+27532.9% | $4K-67.5% | $11K-97.8% | $497K | N/A |
| Inventory | $253K | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.7M+355.5% | $1.7M-91.8% | $20.5M-93.4% | $310.1M+105492.1% | $294K |
| Current Liabilities | $7.6M+349.8% | $1.7M+318.5% | $403K+33.0% | $303K+3.3% | $294K |
| Total Equity | -$6.4M-314.0% | -$1.5M-215.7% | -$488K+95.1% | -$9.9M-2092089.7% | -$475 |
| Retained Earnings | -$27.3M-881.5% | -$2.8M+75.4% | -$11.3M-13.6% | -$9.9M-38913.2% | -$25K |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
ASBPW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M | -$4.9M-1756.6% | -$265K+59.4% | -$653K+53.6% | -$1.4M-490.4% | -$239K |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$294.7M | N/A |
| Financing Cash Flow | $19.1M | $5.9M+2199.2% | $258K | N/A | $296.6M+124207.8% | $239K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASBPW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Gross Margin | -1.9% | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | 22.3%+21.2pp | 1.1%+9.8pp | -8.7% |
| Current Ratio | 0.17+0.1x | 0.09-0.1x | 0.20-3.4x | 3.62+2.6x | 1.00 |
Not reported in any period shown, so not listed: Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$6.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Aspire Biopharma Holdings Inc Ranks
Frequently Asked Questions
What is Aspire Biopharma Holdings Inc's annual revenue?
Aspire Biopharma Holdings Inc (ASBPW) reported $6K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Aspire Biopharma Holdings Inc's gross margin?
Aspire Biopharma Holdings Inc (ASBPW) had a gross margin of -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aspire Biopharma Holdings Inc's operating cash flow?
Aspire Biopharma Holdings Inc (ASBPW) recorded an outflow of $4.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aspire Biopharma Holdings Inc's total assets?
Aspire Biopharma Holdings Inc (ASBPW) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aspire Biopharma Holdings Inc spend on research and development?
Aspire Biopharma Holdings Inc (ASBPW) invested $924K in research and development during fiscal year 2025.
What is Aspire Biopharma Holdings Inc's current ratio?
Aspire Biopharma Holdings Inc (ASBPW) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aspire Biopharma Holdings Inc's cash runway?
Based on fiscal year 2025 data, Aspire Biopharma Holdings Inc (ASBPW) had $1.0M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aspire Biopharma Holdings Inc's debt-to-equity ratio negative or not reported?
Aspire Biopharma Holdings Inc (ASBPW) has negative shareholder equity of -$6.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.